Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab.
Bowel metastasis and perforation in patients with non-small cell lung cancer is rare. Bevacizumab has emerged as a new therapy in the treatment of metastatic non-small cell lung cancer. Bowel perforation associated with its use has been described in colon and ovarian cancers. The exact mechanism by which perforation occurs is under debate, and many theories exist. In this report, we present the first known case of visceral perforation in a patient with metastatic non-small cell lung cancer after treatment with bevacizumab.
Gray
Jhanelle
J
Department of Thoracic Oncology, Yale-New Haven Medical Center, New Haven, Connecticut, USA.
Murren
John
J
Sharma
Anupama
A
Kelley
Scott
S
Detterbeck
Frank
F
Bepler
Gerold
G
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D007416:Intestinal Perforation / Q000209:etiology*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab